A Comparison of the Dissolution and Bioavailability Characteristics of Three Spironolactone Tablet Formulations, Including Preliminary Data on Two Spironolactone Metabolites
- 1 March 1976
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 4 (2) , 86-95
- https://doi.org/10.1177/030006057600400202
Abstract
The bioavailabilities of three spironolactone tablet formulations specially selected for major differences in in vitro dissolution tests were compared in normal male volunteers by measuring plasma and urinary levels of the pharmacologically active spironolactone metabolite canrenone. It was possible to demonstrate small but statistically significant differences in plasma canrenone concentration-time curves derived from the three formulations together with significant differences in the time course of urinary canrenone excretion. The bioavailabilities of the three formulations did not differ significantly although the tablet with the poorest in vitro dissolution produced a significantly delayed peak canrenone concentration. The dissolution rate methodology and results are described and an approach to the development of improved in vitro dissolution tests for spironolactone is suggested. The use of a new method for canrenone estimation resulted in the incidental detection of two other quantitatively significant spironolactone metabolites and preliminary information is given on these.This publication has 17 references indexed in Scilit:
- USE OF DIURETICS IN THE TREATMENT OF KIDNEY DISEASES*Annals of the New York Academy of Sciences, 2006
- Comparison of Spironolactone Tablet Dosage Forms in Healthy HumansJournal of Pharmaceutical Sciences, 1974
- Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone®)Steroids, 1972
- Comparison of Surgery and Prolonged Spironolactone Therapy in Patients with Hypertension, Aldosterone Excess, and Low Plasma ReninBMJ, 1972
- Gas chromatographic determination of levels of aldadiene in human plasma and urine following therapeutic doses of spironolactoneJournal of Chromatography A, 1971
- Oral Absorption with Various Preparations of Spironolactone in DogsJournal of Pharmaceutical Sciences, 1964
- Inactive Prednisone Tablets U.S.P. XVIJournal of Pharmaceutical Sciences, 1963
- GASTROINTESTINAL ABSORPTION OF SPIRONOLACTONEThe Lancet, 1962
- EFFECT OF A DETERGENT ON GASTROINTESTINAL ABSORPTION OF A STEROIDThe Lancet, 1961
- AN ALDOSTERONE ANTAGONIST AND DIURETICS IN THE TREATMENT OF CHRONIC ŒDEMA AND ASCITESThe Lancet, 1960